Phenotypic hypersusceptibility to non-nucleoside reverse transcriptase inhibitors in treatment-experienced HIV-infected patients: impact on virological response to efavirenz-based therapy
- 1 June 2001
- journal article
- research article
- Published by Wolters Kluwer Health in AIDS
- Vol. 15 (9) , 1125-1132
- https://doi.org/10.1097/00002030-200106150-00007
Abstract
Enhanced susceptibility to non-nucleoside reverse transcriptase inhibitors (NNRTI) was recently described in association with increased resistance to nucleoside analogs (nucleoside reverse transcriptase inhibitors; NRTI). To determine the prevalence of NNRTI hypersusceptibility, the genotypic correlates, and its impact on virologic response to efavirenz-based salvage therapy. Genotype and phenotype testing was performed retrospectively on baseline isolates from 30 patients who received salvage therapy containing efavirenz. NNRTI hypersusceptibility was defined as a 50% inhibitory concentration (IC50) of < 0.5 that of the wild-type control. Eight isolates had major NNRTI mutations. Among the 22 isolates with no major NNRTI mutations, 11 (50%) were hypersusceptible to efavirenz, 10 (45%) to delavirdine, and eight (36%) to nevirapine. Among eight isolates with NNRTI mutations, NNRTI resistance was present, but at lower than expected levels. The number of NRTI mutations was correlated inversely with the fold decrease in susceptibility to efavirenz (Spearman's ρ, −0.57;P = 0.005), delavirdine (ρ, −0.43;P = 0.04), and nevirapine (ρ, −0.69;P < 0.001). Excluding subjects with NNRTI mutations, subjects with efavirenz hypersusceptibility at baseline had significantly better virologic suppression over 24 weeks than those without efavirenz hypersusceptibility (P < 0.001). NNRTI hypersusceptibility is common in heavily treated but NNRTI naive patients and is related directly to NRTI resistance mutations. Among patients receiving efavirenz-containing regimens, NNRTI hypersusceptibility was associated with an improved virologic outcome after 24 weeks of therapy. A reversal of phenotypic resistance was seen in patients with NNRTI mutations in the presence of multiple NRTI mutations, but no obvious virologic benefit of this phenomenon was seen in this study.Keywords
This publication has 17 references indexed in Scilit:
- Human Immunodeficiency Virus Type 1 Mutations Selected in Patients Failing Efavirenz Combination TherapyAntimicrobial Agents and Chemotherapy, 2000
- Rapid Communication: Efavirenz- and Adefovir Dipivoxil–Based Salvage Therapy in Highly Treatment-Experienced Patients: Clinical and Genotypic Predictors of Virologic ResponseJAIDS Journal of Acquired Immune Deficiency Syndromes, 2000
- Antiretroviral Therapy in AdultsJAMA, 2000
- Efavirenz plus Zidovudine and Lamivudine, Efavirenz plus Indinavir, and Indinavir plus Zidovudine and Lamivudine in the Treatment of HIV-1 Infection in AdultsNew England Journal of Medicine, 1999
- A 6-basepair insert in the reverse transcriptase gene of human immunodeficiency virus type 1 confers resistance to multiple nucleoside inhibitors.Journal of Clinical Investigation, 1998
- A Randomized, Double-blind Trial Comparing Combinations of Nevirapine, Didanosine, and Zidovudine for HIV-Infected PatientsJAMA, 1998
- HIV-1 Drug Susceptibilities and Reverse Transcriptase Mutations in Patients Receiving Combination Therapy with Didanosine and DelavirdineJAIDS Journal of Acquired Immune Deficiency Syndromes, 1997
- Comprehensive mutant enzyme and viral variant assessment of human immunodeficiency virus type 1 reverse transcriptase resistance to nonnucleoside inhibitorsAntimicrobial Agents and Chemotherapy, 1993
- 3'-Azido-3'-deoxythymidine resistance suppressed by a mutation conferring human immunodeficiency virus type 1 resistance to nonnucleoside reverse transcriptase inhibitorsAntimicrobial Agents and Chemotherapy, 1992
- Human immunodeficiency virus type 1 mutants resistant to nonnucleoside inhibitors of reverse transcriptase arise in tissue culture.Proceedings of the National Academy of Sciences, 1991